US FDA, EMA, Health Canada and other regulators are having to tackle shortages and discontinuations of oncology drugs like cyclofosfamide, methotrexate, Vizimpro (dacomitinib) and supportive care agents like allopurinol. What’s the recourse?
US FDA, EMA, Health Canada and other regulators are having to tackle shortages and discontinuations of oncology drugs like cyclofosfamide, methotrexate, Vizimpro (dacomitinib) and supportive care agents like allopurinol. What’s the recourse?